The Magazine for Sleep Professionals
Sunday, August 30, 2026
There I was—in class again. Tired again. Such is the life of a graduate student. When you’re going to class, working, and completing an internship, “tired” is the norm. As I woke up from one of my many naps that day, I saw that today’s class was on sleep disorders, […]
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]
Philips announced that Philips Respironics DreamStation BiPAP AVAPS devices, which include S, T, S/T, and PC modes with AVAPS, are available for sale in the United States for new set-ups for patients with obstructive sleep apnea (OSA) and respiratory impairment, who are both >7 years of age and weighing 40-66lbs. The […]
Sleep.ai announced findings from a peer-reviewed study led by Washington State University, in collaboration with the University of Washington, exploring sleep patterns in people with chronic insomnia. It is the longest known objective, real-world characterization of objective sleep in chronic insomnia. Published in JMIR Formative Research, the study tracked 112 adults […]
Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026. The study, titled: “Modulating […]
